Intressa Vascular

The company's lead product is the Allay™ Aortic Stent, a treatment for Type B aortic dissections (TBAD) and residual dissections. This device is designed to recentralize blood flow within the aorta's true lumen, securing the dissection flap against the aortic wall while preserving blood flow to critical branch arteries through its porous, open-cell design. A key benefit is its availability as a ready-to-treat stent, which minimizes delays associated with customization and is supported by sizing software for personalized procedural planning. The goal is to offer a streamlined, minimally invasive procedure with a low risk of complications like paraplegia or stroke.

Intressa Vascular targets the endovascular treatment market for aortic dissection, an addressable segment estimated at €1.8 to €2.3 billion. The company's business model centers on developing and bringing this patented technology to market, with revenue expected from the sale of the Allay® Aortic Stent to specialized aortic treatment centers. The company is actively engaged in clinical trials, such as the DRAGON and EXTENSO studies, to validate the safety and efficacy of its device and support product registration in key markets, including the USA, Europe, and China.

Between 2021 and 2023, the company secured significant financing totaling €31 million through a combination of equity rounds and non-dilutive funding to advance its clinical development and product registration. Key investors include Noshaq, Yonjin Capital, the White Fund, and SRIW, with additional support from the Walloon Region. The leadership team, led by CEO Pierre Douette and CSO Diane Lejeune, possesses extensive experience in medical technology, clinical affairs, and regulatory strategy.